Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 47: 594-597, 2001;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porsch-Özçürümez, M.
Right arrow Articles by Luley, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porsch-Özçürümez, M.
Right arrow Articles by Luley, C.
(Clinical Chemistry. 2001;47:594-597.)
© 2001 American Association for Clinical Chemistry, Inc.


Technical Briefs

Measurement of Low Apolipoprotein Concentrations by Optimized Immunoturbidimetric Applications

Mustafa Porsch-Özçürümez1,a, Sabine Westphal2 and Claus Luley2

1 Institute of Clinical Chemistry, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany

2 Institute of Clinical Chemistry, University of Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany
a address correspondence to this author at: Universitätsklinikum Regensburg, Institut für Klinische Chemie und Blutbank, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany; fax 49-941-944-6202, e-mail mustafa.porsch-oezcueruemez{at}klinik.uni-regensburg.de

Apolipoproteins define the functional properties of lipoprotein particles. In addition to their stabilizing features, several apolipoproteins have ligand functions. Some are also responsible for the modulation of enzymes involved in the homeostasis of lipid metabolism. Thus, apolipoprotein concentrations may provide essential information about lipid metabolism and associated diseases. There is evidence, for example, that apolipoprotein concentrations provide clinically relevant information concerning risk for coronary heart disease (1).

The determination of apolipoproteins in distinct lipoprotein subfractions narrows the conclusions that can be drawn for risk assessment as determined by or the discriminative power of HDL- and LDL-cholesterol (2)(3). In research, the determination of apolipoproteins encompasses their measurement in cell culture supernatants (4), lipoprotein subfractions separated by ultracentrifugation (5), isotachophoresis (6), immunoaffinity chromatography (7), or size-exclusion chromatography (8). The measurement of apolipoproteins in samples derived from such procedures requires appropriate methods reliable at concentrations below the physiological range.

Five analytical techniques are commonly used to quantify apolipoproteins. No delipidation is necessary in any of the advanced assays.

The use of radioactive reagents in RIAs is problematic (9). Radial immunodiffusion (RID) is simple to perform but time-consuming. Difficulties can occur when analyzing lipemic sera if the diffusion of the lipoprotein particles is complicated by particle size (5). Electroimmunodiffusion using the Laurell-Rocket technique (9) requires less time than RID, but large amounts of antibodies are needed. ELISAs provide several advantages (10), including good precision and a sensitivity comparable to RIAs. ELISAs are useful in routine clinical determinations because of the availability of automated methods. Nephelometry and immunoturbidimetry provide additional advantages in apolipoprotein measurement (11)(12). Whereas ELISAs are highly sensitive, nephelometry and immunoturbidimetry are superior with respect to precision, time, and cost. Therefore, nephelometry and immunoturbidimetry seem to be the most suitable methods for routine analysis of apolipoproteins.

To improve the relatively low sensitivity compared with ELISA, we optimized and evaluated immunoturbidimetric applications for low concentrations of the most frequently measured apolipoproteins, i.e., apolipoprotein (Apo)A-I, ApoA-II, ApoB, ApoC-III, and ApoE, attaining 12.5- to 45-fold higher sensitivities for these assays.

Commercially available assays for ApoA-I and ApoB ("ApoA1, immunologischer Trübungstest" and "ApoB, immunologischer Trübungstest") were obtained from Rolf Greiner Biochemica and modified to measure physiological concentrations of ApoA-II, ApoC-III, and ApoE. Assays were performed on a Hitachi 911 automated analyzer (Boehringer Mannheim).

The application characteristics of assays for physiological applications and the final low-range conditions are given in Table 1 . Initially, samples were incubated for 5 min with buffer 1 ("Immunofluid"; Greiner Biochemica) containing different concentrations of polyethylene glycol (PEG 10000) dissolved and stabilized in 100 mmol/L Tris buffer (pH 7.5) as provided ready to use by the manufacturers. Sample volumes were increased 10- to 12.5-fold in low-range applications. Commercially available human polyclonal goat antibodies specific against ApoA-I, A-II, B, C-III, and E (Rolf Greiner Biochemica) were used without additional dilution in all assays. Antisera were added after the first incubation step. The resulting absorbance was determined after an incubation interval of another 5 min.


View this table:
[in this window]
[in a new window]
 
Table 1. Assay settings and performance characteristics.

Calibrators and control sera were purchased from Behringwerke ["N-Apolipoprotein" and "Apolipoprotein Control Serum CHD (human)"]. Analytical values of ApoA-I and ApoB were based on IFCC reference preparations (13). For ApoE, reference values provided by the manufacturers for nephelometry were used. The ApoC-III concentration of the N-Apolipoprotein standard was repeatedly measured by RID, and the mean value was used for calibration. Calibrators for the low-range applications were within the experimentally determined linearity range (see below) starting with a dilution of 1:16 of the N-Apolipoprotein standard. In all assays, a six-point calibration was performed. Sample concentrations were estimated by the logit-log method.

Low-range turbidimetry was compared with ELISA on an ES700 automated analyzer (Boehringer Mannheim). The preparation and performance characteristics of the ELISAs are described below. Polyclonal goat antibodies used for turbidimetry were purified by affinity chromatography, using HDL- or LDL-Sepharose 4B (Amersham-Pharmacia-Biotech). After elution with 3 mol/L sodium thiosulfate, antibodies were dialyzed against 1 mol/L phosphate-buffered saline and aliquoted. Subsequently, the portion used as primary antibody was stored at -20 °C until used. A portion of the affinity-purified antibodies was biotinylated, dialyzed extensively to remove the excess unbound biotin, and used as secondary antibody. The reactivities of the primary and secondary antibodies were confirmed by clearly visible precipitation bands within 48 h after diffusion of each antibody lot against human serum on Ouchterlony plates. Uncoated test tubes ("Enzym-Test System, uncoated tubes, naturel"; Boehringer Mannheim) were coated overnight with the primary antibody diluted 1:1000 with 66.7 mmol KH2PO4 and 66.7 mmol Na2HPO4 (pH 6.0) and were subsequently blocked with 20 mL/L bovine serum albumin (BSA). Secondary antibodies were then added to the plates; anti-ApoB antibodies were diluted 1:4000 with 10 g/L BSA, and the remaining antibodies were diluted 1:2000. After the reaction, streptavidin-coupled horseradish peroxidase and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) were added to the plates, and the resulting product was detected at 422 nm. Calibrators and control sera used were identical to those used for immunoturbidimetry. Control sera were diluted 1:7500 in 70 mL/L BSA. Samples used for method comparison were diluted 1:750 to obtain absorbances within the linearity range of the assays. All samples belonging to the same comparison series were measured in the same batch. The CVs for all of the ELISAs were <=5%.

The imprecision (as CVs) of the low-range assays (Table 1Up ) was determined according to NCCLS protocol EP5-T2 (14). Although the CVs for ApoA-I, A-II and B assay were <5%, those for ApoC-III and E were higher. Because CVs are particularly critical at low concentrations, we determined the functional assay sensitivity contiguously in these ranges. The interassay CVs calculated from 10 measurements on 10 consecutive days are depicted in Fig. 1A . ApoA-I, A-II, and B exhibited between-assay CVs <5% over a broad concentration range. The CVs increased at 25 mg/L (ApoA-I), 10 mg/L (ApoA-II), and 15 mg/L (ApoB). For ApoC-III and ApoE, the CV patterns differed considerably. The between-assay CVs for ApoC-III steadily increased as the concentration decreased over the entire linearity range, reaching 10% at 1.4 mg/L and 20% at 0.3 mg/L. The between-assay CVs for ApoE were robust down to 1 mg/L. Below this threshold, a large increase in the CV was observed. CVs exceeding the 20% cutoff were calculated for ApoE concentrations <0.4 mg/L.



View larger version (27K):
[in this window]
[in a new window]
 
Figure 1. Functional assay sensitivity (A), method comparison (B), and linearity ranges (C).

(A), functional assay sensitivity for immunoturbidimetrically determined apolipoprotein concentrations. Each data point (n = 96) represents the interassay CV calculated from 10 measurements on 10 consecutive days using aliquoted samples stored at -20 °C. (B), independent samples (n = 30) were simultaneously assayed for method comparison between immunoturbidimetry (x-axis) and ELISA (y-axis). For A and B, samples were diluted 1:2, 1:5, or 1:10 with 70 mL/L BSA to obtain appropriate concentrations. Samples in A and B were not identical. (C), linearity ranges of immunoturbidimetric apolipoprotein assays. Samples were diluted with 70 mL/L BSA. Data are means (mg/L) of two determinations. {blacksquare}, ApoA-I; {blacktriangledown}, ApoB; {circ}, ApoC-III; {triangleup}, ApoE; {square}, ApoA-II. Range for ApoA-II (0–80 mg/L) shown on right. Ranges for ApoA-I and ApoB (0–300 mg/L) and ApoC-II and ApoE (0–10 mg/L) shown on left.

Because in some of the assays, repeatedly measured blanks did not differ from zero, the lowest concentration different from blank values (detection limit) was estimated by the calibration curve method (15), using the above-described calibration sera. In all calculations, an {alpha} error of 0.05 was assumed. Calibration curves were generated by single measurements of six calibration points. The following equation was used, assuming {alpha} = ß:

where

The resulting detection limits for normal- and low-range applications are given in Table 1Up . Improvements were 12.5-, 45-, 15-, 32.5-, and 22.5-fold for ApoA-I, A-II, B, C-III, and E, respectively.

The assays were linear up to 65 mg/L for Apo A-II and 8 mg/L for Apo C-III and ApoE. For ApoA-I and ApoB, a high-dose hook effect attributable to antigen excess was observed starting at 275 mg/L (ApoA-I) and 150 mg/L (ApoB), respectively. However, because of the wide overlap between the detection limit of all normal-range assays (Table 1Up ) and the linearity range given for the low-range applications (Fig. 1CUp ), these problems could be circumvented by the simultaneous use of both applications for each marker, which is recommended to detect unexpected outliers. Because high salt concentrations also hamper antibody reactivity, we checked the recovery of all five apolipoproteins in high ionic strength environments. Potassium bromide solutions with densities up to 1.25 g/L are used to isolate lipoprotein fractions by sequential ultracentrifugation. Within the range 1.0–1.25 g/L, no decrease of recovery was observed for samples at the lower and upper ends of the linearity ranges of the respective applications (data not shown). At higher salt concentrations, samples had to be desalted before analysis because the recovery progressively decreased.

The comparison of low-range turbidimetric assays with ELISA methods are shown in Fig. 1BUp . Immunoturbidimetry slightly overestimated apolipoprotein concentrations except for ApoB. The most critical discrepancy again was observed for ApoE, which exhibited a regression coefficient of 0.869. In contrast, immunoturbidimetry underestimated ApoB by 10%. Correlation coefficients of all method comparisons performed underlined the good agreement of both methods.

Taken together, our results indicate that for apolipoprotein concentrations below the physiological range, our immunoturbidimetric methods offers features that are comparable to other more time-consuming, costlier techniques such as ELISA. Taking into consideration that both the low- and normal-range applications can be set up easily and in parallel on most currently used random-access analyzers, the proposed applications might be a helpful alternative to previous methods, even when there is a demand for the precise determination of low apolipoprotein concentrations. We therefore conclude that the described methodology is appropriate for rapid determination of apolipoproteins in research and routine diagnostic determinations.


References

  1. Genest JJ, Jr, Bard JM, Fruchart JC, Ordovas JM, Wilson PW, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991;90:149-157.[Web of Science][Medline] [Order article via Infotrieve]
  2. Alaupovic P, Blankenhorn DH. [Determination of potentially atherogenic triglyceride-rich lipoprotein particles] Bestimmung von potentiell atherogenen triglyzeridreichen Lipoprotein-Partikeln. Klin Wochenschr 1990;68(Suppl 22):38-42.
  3. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996;122:105-115.[Web of Science][Medline] [Order article via Infotrieve]
  4. Duverger N, Rader D, Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, et al. Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. Eur J Biochem 1995;227:123-129.[Web of Science][Medline] [Order article via Infotrieve]
  5. Fruchart JC, Marcovina SM, Puchois P. Laboratory measurement of plasma lipids and lipoproteins. Lipoprotein quantification. Fruchart JC Sheperd J eds. Human plasma lipoproteins 1989:89-112 Walter de Gruyter Berlin. .
  6. Bottcher A, Mollers C, Lackner KJ, Schmitz G. Automated free-solution isotachophoresis: instrumentation and fractionation of human serum proteins. Electrophoresis 1998;19:1110-1116.[Web of Science][Medline] [Order article via Infotrieve]
  7. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families. Lee MD eds. Progress in lipid research: chemistry and metabolism of lipoprotein particles 1991:105-138 Pergamon Press Oxford. .
  8. Orth M, Hanisch M, Kroning G, Porsch-Ozcurumez M, Wieland H, Luley C. Fluorometric determination of total retinyl esters in triglyceride-rich lipoproteins. Clin Chem 1998;44:1459-1465.[Abstract/Free Full Text]
  9. Curry MD, Gustafson A, Alaupovic P, McConathy WJ. Electroimmunoassay, radioimmunoassay, and radial immunodiffusion assay evaluated for quantification of human apolipoprotein B. Clin Chem 1978;24:280-286.[Abstract/Free Full Text]
  10. Labeur C, Shepherd J, Rosseneu M. Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clin Chem 1990;36:591-597.[Abstract/Free Full Text]
  11. Weisweiler P, Schwandt P. Determination of human apolipoproteins A-I, B, and E by laser nephelometry. J Clin Chem Clin Biochem 1984;22:113-118.[Web of Science][Medline] [Order article via Infotrieve]
  12. Heuck CC, Erbe I, Flint Hansen P. Immunonephelometric determination of apolipoprotein A-1 in hyperlipoproteinemic serum. Clin Chem 1983;29:120-125.[Abstract/Free Full Text]
  13. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-662.[Abstract/Free Full Text]
  14. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices, 2nd ed.; tentative guideline. NCCLS Document EP5–T2. Wayne, PA: NCCLS, 1992..
  15. Arbeitsausschuss Chemische Technologie im Deutschen Institut für Normung e.V. [Chemical analysis; decision limit. detection limit and determination limit; Estimation in case of repeatability, terms, methods, evaluation.] DIN 32 645. Berlin: Beuth Verlag GmbH, May 1994..




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porsch-Özçürümez, M.
Right arrow Articles by Luley, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porsch-Özçürümez, M.
Right arrow Articles by Luley, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS